Clinical trials: Cell, Circulating Tumor
Circulating Tumor Cells (CTCs)
Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients
To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and…
- Trial name
- NCT02904135
- Where
- Taiwan
- Volunteers
- 141 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in prostatic cancer could play an important role in…
- Trial name
- NCT02450435
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Melanoma
Analysis of Circulating Exosomes in Melanoma Patients
The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma.
- Trial name
- EXOMEL1 (NCT05744076)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Meningioma
Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study
The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.
- Trial name
- BIOLIMEN-1 (NCT07398170)
- Testing
- Blood sampling, Lumbar puncture
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Melanoma
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
The purpose of this study is to evaluate if precisely-targeted radiation therapy, known as stereotactic ablative radiotherapy (SART), given during treatment with the drug ipilimumab (Yervoy) will improve survival for patients…
- Trial name
- SART (NCT01565837)
- Testing
- Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wolfram Samlowski
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung Cancer
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
Immunotherapy is probably, since the development of therapies targeting EGFR mutations or ALK rearrangement, the most attractive therapeutic perspective in the management of metastatic lung cancer.
- Trial name
- IMMUNO-PREDICT (NCT02827344)
- Testing
- blood sample collection for CTC and MDSC analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal…
- Conditions
- Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
- Trial name
- CheckMate 9TN (NCT03770299)
- Testing
- Nivolumab, Vinorelbine, Gemcitabine
- Sponsor
- Bristol-Myers Squibb
Cancer of Rectum, Cancer of Pancreas
LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS
This is a prospective, observational, multicenter cohort study. Our main objective is to to evaluate the use of CTCs and ctDNA with prognostic factors in locally advanced rectal tumors treated with total neoadjuvant therapy…
- Conditions
- Cancer of Rectum, Cancer of Pancreas, Cancer of Stomach
- Trial name
- BLENTI (NCT06940778)
- Testing
- No Interventions
- Where
- Brazil
- Volunteers
- 273 people
- Sponsor
- Hospital do Coracao
Cervical Cancer, Recurrent Cervical Cancer
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis…
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Trial name
- NCT07673211
- Testing
- Biospecimen collection (peripheral blood and paraffin tumor tissue)
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Breast Cancer
Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer
A prospective, single-centre, proof-of-concept pilot study in patients with metastatic breast cancers (MBC) (whatever the immunohistochemical subtype) treated at the IUCT-O.
- Trial name
- DP METABREAST (NCT06408038)
- Testing
- For each patient included, the samples described below will be collected:
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Prostate Cancer
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml).
- Trial name
- NCT03488706
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- CellMaxLife
Resectable Non-small Lung Cancer
Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer
With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer.
- Trial name
- LYMPHOLUNG (NCT02551211)
- Testing
- blood drawn, surgical resection of cancer
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Lung Cancer
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
- Trial name
- NCT04814407
- Testing
- Blood-derived DNA methylation detection
- Where
- Taiwan
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Brain Cancer, Breast Cancer
Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer
This study assesses the number of CTCs before and 4-5 weeks after focal stereotactic radiotherapy, in single or fractionated dose, and correlate with the local and distant brain progression-free survival in patients with…
- Trial name
- NCT02941536
- Testing
- Circulating tumor cells evaluation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- AC Camargo Cancer Center
Pancreatic Adenocarcinoma
PDAC Peripheral and Portal Vein Sampling
This is a research study in which bio-specimens (whole blood, plasma and serum from peripheral circulation and portal vein) will be collected from patients with pancreatic adenocarcinoma for translational research.
- Trial name
- NCT04289961
- Testing
- Portal vein sampling
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- The Christie NHS Foundation Trust
Uveitis, Lymphoma
Screening for Oculocerebral Lymphoma With the Phenotype of NK Cells in Patients With Uveitis
Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor.
- Conditions
- Uveitis, Lymphoma, NK-Cell Lymphoma
- Trial name
- DeLPHy (NCT05388838)
- Testing
- Blood sample
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon